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Advances in sepsis-associated liver dysfunction
Introduction
Sepsis reflects a systemic inflammatory syndrome in 
response to an infection and represents the leading cause 
of  death in the intensive care unit.[1] The predominant 
cause of  morbidity and mortality is the development 
of  multiple organ dysfunction syndrome (MODS) with 
subsequent organ failure. During the process of  sepsis, 
the liver plays an important role in defensive responses to 
scavenge bacteria and produce inflammatory mediators. 
But the liver also acts as a potential target of  dysregulated 
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inflammatory response. Sepsis-associated liver dysfunc-
tion is traditionally viewed as a late feature of  critical 
illness, manifesting jaundice and hyperbilirubinemia. 
However, recent studies have revealed liver dysfunction 
as an early event in sepsis.[2] Liver dysfunction is not the 
most common form of  organ injury encountered in septic 
patients; when it culminates into liver failure, it becomes 
a grave complication. Therefore, it is important to under-
stand the pathophysiological changes that contribute to 
liver dysfunction associated with sepsis, which has been 
defined as the combination of  cellular injury in addition 
to heightened inflammation. This review will focus on 
the pathophysiological alterations, clinical characteristics 
and therapeutic considerations of  sepsis-associated liver 
dysfunction.
Key points
• Sepsis-associated liver dysfunction is usually attributed 
to systemic or microcirculatory disturbance.
A B S T R A C T
Recent studies have revealed liver dysfunction as an early event in sepsis. Sepsis-associated liver dysfunction is mainly resulted from 
systemic or microcirculatory disturbances, spillovers of bacteria and endotoxin (lipopolysaccharide, LPS), and subsequent activa-
tion of infl ammatory cytokines as well as mediators. Three main cell types of the liver which contribute to the hepatic response in 
sepsis are Kupﬀ er cells (KCs), hepatocytes and liver sinusoidal endothelial cells (LSECs). In addition, activated neutrophils, which 
are also recruited to the liver and produce potentially destructive enzymes and oxygen-free radicals, may further enhance acute 
liver injury. The clinical manifestations of sepsis-associated liver dysfunction can roughly be divided into two categories: Hypoxic 
hepatitis and jaundice. The latter is much more frequent in the context of sepsis. Hepatic failure is traditionally considered as a late 
manifestation of sepsis-induced multiple organ dysfunction syndrome. To date, no specifi c therapeutics for sepsis-associated liver 
dysfunction are available. Treatment measure is mainly focused on eradication of the underlying infection and management for se-
vere sepsis. A better understanding of the pathophysiology of liver response in sepsis may lead to further increase in survival rates.
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• Four main cell types which contribute to the hepatic 
response in sepsis are Kupffer cells (KCs), neutrophils, 
hepatocytes and liver sinusoidal endothelial cells (LSECs).
• Kupffer cells release cytokines, reactive oxygen species, 
and nitric oxide (NO) which induce LSEC and hepatocyte 
injury.
• Neutrophils, which are recruited to the liver and 
produce pro-inflammatory cytokines and chemokines, 
may further injure LSECs and hepatocytes.
• Abnormalities in quantity, morphology, and function 
of  LSECs developed during sepsis.
• Sepsis induces a profound alteration in the hepatic 
ability to transport bile acids and bilirubin into the 
hepatic canaliculi, thereby causing cholestasis.
• Sepsis-associated liver dysfunction can roughly be 
divided into hypoxic hepatitis and jaundice. The latter 
is much more frequent in the context of  sepsis.
• Treatment measure is mainly focused on eradication 
of  the underlying infection and management for severe 
sepsis.
Pathophysiological changes in sepsis-
associated liver dysfunction
Systemic and microcirculatory disturbances
Sepsis-associated liver dysfunction is usually attributed to 
systemic or microcirculatory disturbance. Numerous studies 
have been shown that there is a consistent correlation of  
cardiac output and macrovascular hepatosplanchnic inflow 
in sepsis. In septic shock, splanchnic blood flow and cardiac 
output are increased but not sufficient to counterbalance the 
high demands for oxygen and the inability of  liver cells to 
extract oxygen.[3] Vascular mechanisms of  defense against 
portal blood flow reduction are also altered, especially the 
defective hepatic arterial response.[4]
Microvascular tissue perfusion in severe sepsis is often 
uncoupled from the systemic circulation. Redistribution of  
intrahepatic blood flow in concert with a complex interplay 
between sinusoidal endothelial cells, liver macrophages, 
and passing leukocytes lead to a decreased perfusion and 
blood flow velocity in the liver sinusoids.[5] Activation and 
dysfunction of  the endothelial cell barrier elicits a significant 
recruitment of  both leukocytes and platelets in the liver 
microvasculature. Subsequently, formation of microthrombi 
further enhances liver tissue ischemia and damage. Emerg-
ing evidence implies that lipopolysaccharide (LPS)-induced 
intrahepatic endothelial dysfunction and microvascular 
disorder could be prevented by simvastatin.[6]
Substances that regulate vascular tone, such as NO, hydrogen 
sulfide (H
2
S), endothelin-1 and carbon monoxide (CO), are 
highly active during sepsis. For  example, inducible NO syn-
thase (iNOS)-derived NO is considered to be a contributor 
to the blood-cell recruitment, and the strong upregulation 
of  iNOS might contribute to a microvascular dysfunction 
and hepatic injury.[7] In contrast, endothelial NO synthase 
(eNOS) appears to play a protective role in liver microcircu-
lation during polymicrobial sepsis. Sepsis-related increase 
in bilirubin level, international normalized ratio, and lipid 
peroxidation in liver tissue were significantly attenuated by 
the early neuronal NO synthase (nNOS) and delayed iNOS 
blockade.[8] Additionally, H
2
S contributes to microcirculatory 
dysfunction in the systemic as well as hepatic microcircula-
tions due to a differential vasoactive function on presinusoidal 
and sinusoidal sites within the liver.[9]
KCs
KCs are presumed to be the primary defense against portal 
bacteremia and endotoxemia. They prevent bacteria and 
endotoxins from entering the systemic circulation by remov-
ing them from the portal vein blood. However, in the case 
of  sepsis, the inflammation cascade is strongly activated. 
Inflammatory response will not only kill the bacteria but 
can also damage the liver. Following excessive LPS stimula-
tion, KCs release cytokines [tumor necrosis factor (TNF)-α, 
interleukin (IL)-1β, IL-6, IL-12 and IL-18], reactive oxygen 
species (ROS) and NO, which induce endothelial cell and 
hepatocyte injury.[10] Lipoprotein and teichoic acid derived 
from Gram-positive bacteria could also activate KCs and 
induce liver injury. Accordingly, KC depletion reduces he-
patic inflammation and apoptosis in abdominal sepsis.[11] 
However, the lack of  IL-10 in KC-depleted mice resulted in 
a detrimental systemic pro-inflammation and a significant 
reduction in survival.
TNF-α is believed to be crucially involved in the develop-
ment of  liver injury in septic complications. TNF-α can 
directly stimulate hepatocytes to induce IL-6 production, 
increases the activity of  cysteinyl aspartate-specific pro-
tease (caspase)-3, and postulates as an important factor 
in the development of  hepatocellular apoptosis.[12] TNF-α 
also activates neutrophils and increases gene expression for 
adhesive molecules, which, in turn, enhances neutrophil 
adherence to sinusoidal endothelial cells in the liver, thus 
contributing to neutrophil-mediated liver injury. It has been 
demonstrated that TNF-α and IL-1β can activate mitogen-
activated protein kinase (MAPK) and decrease multidrug 
resistance protein (MRP)2 expression.[13] Since bilirubin, 
glutathione (GSH), and divalent bile acids are the main 
substrates for MRP2, it is likely that the functional down-
regulation of  MRP2 accounts for the impaired transport of  
these compounds into bile,  resulting in a parallel backflow 
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of  bilirubin from the hepatocyte into the bloodstream cul-
minating in hyperbilirubinaemia. There is a rapid upregula-
tion of  liver IL-6 messenger RNA after LPS exposure. IL-6 
is produced by KCs, hepatocytes, and LSECs after LPS 
stimulation. In combination with IL-1β and TNF-α, IL-6 
markedly enhances gene expression of  acute-phase proteins 
(APP) via transcriptional activation.[14] IL-18, secreted by 
KCs, could activate both TNF-α and Fas ligand-mediated 
hepatocytotoxic pathways in LPS-induced liver injury.[15]
Lastly, increased levels of  ROS have been demonstrated in 
different models of  sepsis and this disturbance may lead to 
DNA, protein, or lipid damage resulting in apoptosis and 
necrosis followed by cell death.
Neutrophils
Accumulation of  neutrophils is an early phenomenon in 
the liver during the development of  sepsis. Neutrophil 
recruitment to the liver is the result of  a complex interac-
tion between neutrophils, sinusoidal endothelium, hepa-
tocytes, and KCs. During the process of  septic response, 
activated KCs release leukotriene B4 and TNF-α, which 
in turn attract blood neutrophils into the liver and activate 
them.[16] Apoptotic hepatocytes have also been shown to 
function as chemotactic signals, triggering neutrophil trans-
migration.[17] Upregulation of  endothelial integrins and 
intercellular adhesion molecule (ICAM)-1 also promotes 
neutrophil migration in LPS-induced liver injury.[18] In 
contrast, heme oxygenase (HO)-1 in neutrophil attenuates 
its infiltration in liver during sepsis via the inactivation of  
p38 MAPK.
Once neutrophils enter the liver, they start several an-
tibacterial activities by secreting proteolytic enzymes 
and ROS. Meanwhile, they can induce the production 
of  pro-inflammatory cytokines and chemokines. These 
mechanisms play major roles in protecting against in-
fection, but they may also injure endothelial cells and 
hepatocytes.[19] For example, a homeostatic balance ex-
ists between the formation of  ROS and their removal by 
endogenous antioxidant scavenging compounds under 
physiological conditions. Continued or excessive produc-
tion of  ROS can be deleterious to mitochondria and other 
organelles.[20] O
2
-and non-oxygen-derived radicals, such as 
NO generated by activated neutrophils, could rapidly react 
with each other to form peroxynitrite (ONOO–), which is 
one of  the highly reactive oxidant species. ONOO– can 
deplete intracellular GSH levels, inhibit mitochondrial 
superoxide dismutase, and oxidize mitochondrial proteins, 
thereby leading to cascades that cause cellular apoptosis 
or necrosis in septic liver.
Hepatocytes
Hepatocytes, via receptors for inflammatory mediators, 
regulate their metabolic pathway toward glycogenolysis, 
gluconeogenesis, amino acid uptake, ureagenesis, as well 
as increased synthesis of  coagulant factors, complement 
factors, and acute-phase proteins, all of  them prioritizing 
protein synthesis and tissue repair. Simultaneously, the 
hepatic production of  albumin, properdin, high-density 
lipoprotein, protein C and antithrombin decreased. During 
the metabolic changes in hepatocytes, KCs are believed to be 
a key regulator through synergistic effects of  TNF-α, IL-1, 
and IL-6.[21] In addition, exogenous mediators, notably LPS, 
have direct and indirect cytotoxic effects on hepatocytes and 
trigger metabolic changes in hepatocytes.
APP (e.g., C-reactive protein, α1-antitrypsin, α2-macroglobulin, 
and thrombin-activatable fibrinolytic inhibitor) contributes to 
the pro-coagulant state. For instance, elevated C-reactive pro-
tein levels promote the expression of tissue factor by mono-
nuclear cells, increase liver production of thrombin-activatable 
fibrinolytic inhibitor, and enhance fibrinolysis inhibition.[22] 
Neutrophils are also a source of tissue factor, and they are 
implicated in direct activation of the coagulation cascade in the 
early phases of sepsis. Study shows that Ca2+ channel blockers 
curb the sepsis-induced acute phase response by preventing 
sepsis-related hepatic Ca2+ changes and thus modulate the 
metabolic response of hepatocytes.[23]
Sepsis induces a profound alteration in the hepatic ability to 
transport bile acids and bilirubin into the hepatic canaliculi, 
thereby causing cholestasis. Visualization of  the hepatobi-
liary excretory function in septic animals demonstrated a 
profound impairment of  hepatocellular transport, specifi-
cally at the canalicular pole.[24] LPS induces KCs to release 
pro-inflammatory cytokines which lead to downregulation 
of  transporters involved in bile flow, coordinated by nuclear 
receptors and transcription factors.[25] The transporters 
that are downregulated include MRP2, organic anion-
transporting polypeptides (OATPs), bile salt export pump 
(BSEP), multiple drug resistance (MDR)-1 transporter, 
Na+, K+-ATPase and sodium-dependent taurocholate 
cotransporting polypeptide (NTCP). Reduced basolateral 
bile acid uptake appears to be related to a reduction in the 
expression of  NTCP and OATPs. Impaired excretion of  
biotransformed molecules from the hepatocyte into the bile 
canaliculi results from a downregulation of  canalicular bile 
acid transporters, including BSEP and MRP2.
In addition, the function of  bile acid transporters can be 
impaired by reduced sinusoidal perfusion and depletion of  
ATP content, pointing to alterations in energy availability as 
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a mechanism of  the biotransformation dysfunction during 
sepsis. The defective expression of  hepatocyte aquaporin-8, 
a water channel involved in bile secretion, also contributes 
to the development of  bile secretory dysfunction in sep-
sis.[26] P-selectin-mediated recruitment of  leukocytes plays 
a potential role in reduction of  bile flow in sepsis-associated 
cholestasis.[27] Moreover, epithelial tight junctions in the 
hepatobiliary system are important in maintaining the 
osmotic gradient for bile production. In the development 
of  severe sepsis, NO secretion could increase tight junction 
permeability in hepatocytes by decreasing zona occludens, 
which were key proteins to maintain tight junctions. Taken 
together, excessive formation of  NO has been implicated in 
playing a role in cholestasis during sepsis.[28]
Apart from impaired hepatobiliary transport, a defect in 
phase I detoxification machinery, including cytochrome 
P450 (CYP450) enzymes (i.e., P450 family CYP1, CYP2 
and CYP3) and phase II conjugating enzymes (glutathione-
S-transferases, bilirubin-UDP-glucuronyl transferase), 
would result in non-detoxification of  substances that 
are normally bile-excreted. The downregulation of  CYP 
enzymes is due to the reduction of  aryl hydrocarbon re-
ceptor (AhR) and AhR nuclear translocator (Arnt), two 
critical transcription factors involved in the regulation of  
CYP1A2 mRNA.[29] Furthermore, AhR and Arnt expres-
sions are inversely correlated with pro-inflammatory cyto-
kines in sepsis. In addition to pro-inflammatory cytokines, 
NO may contribute to the suppression of  CYP in sepsis via 
the interplay of  two different mechanisms: NO-dependent 
suppression of  protein via the enhanced iNOS, and NO-
dependent transcriptional suppression via eNOS.[28] This 
suppression could be reversed by administration of  an NO 
inhibitor.
As for the cellular signal transduction of  impaired biotrans-
formation, phosphatidylinositol 3-kinase (PI3K) is a pivotal 
molecular switch.[30] PI3Kγ–/– mice show preserved mor-
phology and function of  the bile canaliculi in sepsis. PI3K 
signaling also affects hepatic phase I and II metabolism of  
bile acids. Interestingly, neutrophil recruitment into septic 
liver is completely prevented in PI3Kγ–/– mice.
Autophagy is a protective molecular pathway in the setting 
of  sepsis. HO-1-mediated autophagy occurs transiently in 
hepatocytes at an early stage during sepsis.[31] The initial 
elevation of  autophagy may reflect the early host response 
to oxidative stress as well as mitochondrial damage caused 
by septic insult, and protect against hepatocellular death in 
early stages of  sepsis. However, the decline in autophagy at 
late sepsis may cause insufficient recycle function, which 
contributes to hepatic failure. Additionally, altered mem-
brane fluidity and G1 cell cycle arrest in hepatocytes have 
been reported in animal models of  severe sepsis.
Liver sinusoidal endothelial cells
Abnormalities in quantity, morphology, and function of  
LSECs have been reported during experimental sepsis. In 
response to sepsis, LSECs undergo Fas-induced apoptosis, 
culminating in a decrease in overall cell number and an 
increase in liver tissue permeability. KCs could protect 
LSECs from further injury by downregulating gp130 ex-
pression on LSECs.[32] In contrast, KCs could potentiate 
LSEC injury by ligating programmed cell death ligand-1.[33] 
LSECs have the capacity to produce immunoregulatory 
and pro-inflammatory cytokines (e.g., NO, IL-1 and IL-6 ). 
This production is increased when LSECs are treated with 
LPS.[34] LSECs also function as antigen-presenting cells for 
CD4+ T cells, and LPS downregulates CD4+ T cell activa-
tion by antigen-presenting LSECs. In addition, LSECs 
are perforated with fenestrations, pores that facilitate the 
transfer of  lipoproteins and macromolecules between 
blood and hepatocytes. In Gram-negative bacterial sepsis, 
defenestration of  LSECs by bacterial toxins was involved 
in the pathogenesis of  hyperlipidemia.[35] Intravenously 
injected LPS in rats resulted in LSECs enlargement, sieve 
plate disruption, and gap formation.
Other hepatic responses to sepsis
Chronic sequelae of  experimental sepsis are characterized 
by abscess formation, persistent inflammation, and substan-
tial liver injury as well as fibrosis. The latter is associated 
with increased number of  hepatic stellate cells and deposi-
tion of  collagen types I and III.[36] Moreover, significant 
temporal loss of  hepatic B cells was seen following LPS 
challenge. Histological examination shows that hepatitis 
and steatosis are the main findings in the liver in the major-
ity of  patients dying from sepsis.
Sepsis-associated liver dysfunction and MODS
When sepsis-associated liver dysfunction progresses to 
acute liver failure, a cascade of  serious complications (e.g., 
cerebral edema, coagulopathy, cardiovascular instability, 
respiratory failure and renal failure) can occur. In another 
word, sepsis-associated liver dysfunction could induce the 
development of  MODS.
Firstly, superfluous ammonia in acute liver failure (ALF) 
patients is converted to osmotically active glutamine, pro-
ducing osmotic cerebral edema. Impaired cerebral blood 
flow autoregulation, systemic inflammatory response, 
and ischemic injury have also been proposed as the cause 
of  cerebral edema.[37] Secondly, deficiencies of  fibrinolytic 
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proteins, anticoagulant proteins and pro-coagulation factors 
are often present in liver failure; in part due to failure of  syn-
thesis as well as consumption of  these factors. Quantitative 
and qualitative platelet dysfunction is also shown in ALF. 
Thirdly, increased NO production and cyclic guanosine 
monophosphate (GMP) may be involved in cardiovascular 
instability of  ALF patients. Fourthly, direct drug nephro-
toxicity, acute tubular necrosis, and the development of  
abdominal compartment syndrome are common causes of  
renal impairment in ALF.[38] Lastly, acute lung injury/acute 
respiratory distress syndrome (ARDS) is not uncommon in 
ALF; particularly, there is a requirement for vasopressors 
and concurrent intracranial hypertension.
Clinical characteristics of sepsis-associated 
liver dysfunction
Some data showed that liver dysfunction occurs in 34.7% 
of  septic patients.[39] Nevertheless, the incidence of  liver 
dysfunction remains varied because current diagnostic tools 
are lacking, notably those can detect the early liver insults. 
In septic patients, liver dysfunction can vary from subclinical 
injury to overt failure.[40] Sepsis-associated liver dysfunction 
can roughly be divided into hypoxic hepatitis and jaundice. 
Hepatic failure is traditionally considered a late manifesta-
tion of  sepsis-induced multiple organ failure. It is rare if  
the underlying process is detected and adequately treated.
Hypoxic hepatitis
Hypoxic hepatitis is related to hypoperfusion in the pres-
ence of  hypovolemia as well as inadequate cardiac output, 
and it resolves fast under supportive therapy.[41] The leak of  
transaminase enzymes is characteristic of  this injury and 
reflects acute cellular and mitochondrial injury. Aspartate 
aminotransferase (AST) and alanine aminotransferase 
(ALT) are rapidly and markedly elevated after an episode 
of  hypotension or shock, with the predominance of  AST 
over ALT, along with minimal elevation of  gamma-
glutamyltransferase (GGT). AST as well as ALT levels 
were decreased rapidly in a few days once the underlying 
course was corrected. Septic shock with hypoxic hepatitis 
can result in fulminant hepatic failure, which frequently 
leads to disseminated intravascular coagulation and bleed-
ing. Lactate and amino acid clearance, as well as protein 
synthesis are reduced. Gluconeogenesis and glycogenolysis 
are decreased, and hypoglycemia can occur.[42]
Jaundice
The incidence of  jaundice was reported to be 34% in septic 
patients and the overall mortality rate of  these patients 
was 61%. Jaundice is much more frequent than hypoxic 
hepatitis in sepsis. Commonly, jaundice is a late event in 
the course of  severe sepsis. However, jaundice could be 
experienced at an early stage of  sepsis even in the absence 
of  fever or leukocytosis.[43] Both Gram-negative and Gram-
positive bacterial infections could lead to jaundice. In most 
instances of  sepsis-induced jaundice, the infection is intra-
abdominal and may include biliary infection, urinary tract 
infections, or intra-abdominal abscesses. Notably, jaundice 
has also been reported to be associated with pneumonia, 
meningitis, and bacterial endocarditis. Cholestatic liver 
dysfunction is characterized by (supra-) normal tissue per-
fusion. In addition, the elevation of  conjugated bilirubin 
with disproportionately low elevations of  AST, ALT, and 
biliary enzymes is characteristic.[44] Liver histological studies 
showed a predominant intrahepatic cholestasis, which was 
reversible once the infection was controlled.
Prognosis of sepsis-associated liver 
dysfunction
Sepsis-associated liver dysfunction often resolves in paral-
lel with the remission of  sepsis. In contrast, the lack of  
baseline liver dysfunction resolution or the development 
of  new liver dysfunction during the first week of  sepsis or 
both were associated with a lower 28 day survival rate.[45] 
The persistence or development of  liver failure in the 72 h 
period after the onset of  severe sepsis was strongly associ-
ated with a poor outcome.
Serum bilirubin is the most widely used biomarker to diag-
nose hepatic dysfunction during sepsis. In a large Austrian 
multicentric cohort, early increase in plasma bilirubin 
(>2 mg/dl), noted in approximately 10% of  critically ill 
intensive care patients and many of  whom were septic, was 
a strong independent risk factor for subsequent mortality. 
After multivariable adjustment for potential confounding 
factors, elevated serum bilirubin levels within 72 h of  admis-
sion were associated with an increased risk of  mortality in 
patients with severe sepsis and septic shock. [46] However, 
bilirubin level lacks specificity to reflect the full spectrum of  
liver dysfunction and differentiate an acute response from 
a preexisting organ chronic disease.
Recently, it was reported that levels of  both conjugated and 
unconjugated chenodeoxycholic and taurodeox ycholic acid 
were increased in septic patients on the day of  diagnosis, 
and these increased levels showed a stronger correlation 
with 28 day mortality than did bilirubin levels.[30] Similarly, 
plasma disappearance rate of  indocyanine green (PDR
ICG
) 
could detect septic liver dysfunction earlier than changing in 
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bilirubin.[47] This indicator seems to correlate with outcome 
of  patients but lacks information about liver-bile interac-
tions, thereby it fails to evaluate specifically canalicular 
transport, which is an increasingly recognized component 
of  sepsis-associated excretory dysfunction.
Patients aged 61 years or older were prone to sepsis-
associated liver injury, whereas it was rare in patients aged 
15-60 years.[39] Age-related host immunological potency, 
malignant neoplasms, diabetes mellitus, and cerebrovascu-
lar diseases might be potent risk factors in the elderly. Inter-
estingly, development of  jaundice in elderly patients with 
bacterial sepsis was associated with increased survival. This 
result may represent robust immunity in elderly patients 
with sepsis, which might be responsible for their survival.
In the pathophysiological alterations of  sepsis, hepatic 
inflammatory injury depends on the hormonal milieu. A 
higher susceptibility of  liver injury in male individuals and 
protection against liver injury with female hormones has 
been reported in septic animals. As for septic patients, acute 
liver injury was significantly higher in males than in females, 
and the mortality in males was higher than in females.[48]
CYP activity, reflected by the aminopyrine breath test, is 
also a clinically useful tool for predicting outcome in the 
early stages of  sepsis.[49] CYP activity returned to normal 
levels in the survivor patients while they remained low in 
the non-survivors at the late phase of  sepsis.
Therapeutic considerations 
for sepsis-associated liver dysfunction
No specific therapeutics for sepsis-associated liver dysfunc-
tion are currently available. Treatment measure is mainly 
focused on eradication of  the underlying infection and 
management for severe sepsis.[50] Early antibiotic therapy 
and infection source control are essential in improving liver 
function. In addition, an appropriate hemodynamic support 
permits the restoration of  liver perfusion, and it is a criti-
cal step in preventing liver damage. Thus, hemodynamic 
support as recommended is critical (i.e., fluid resuscitation, 
vasopressors, inotropic therapy, and corticosteroids). Dur-
ing the process of  sepsis-related organ dysfunction, good 
management of  extrahepatic organ dysfunction is also 
beneficial in improving liver function.
GSH is widely used as a hepatoprotective drug during 
sepsis in some area. During the initial phase of  sepsis, as 
represented by an intravenous LPS challenge to healthy 
volunteers, plasma concentrations of  total GSH decreased. 
Accordingly, GSH or trophic feeding of  GSH precursors 
amino acid during parenteral nutrition protects against 
peroxidative damage in septic animals.[51] However, clini-
cal studies are needed to confirm the benefit of  GSH, and 
we do not recommend using the drug in the treatment of  
sepsis-associated liver dysfunction.
It is noteworthy that altered biotransformation of  endobiot-
ics and xenobiotics is an important aspect of  perpetuated 
liver damage in sepsis.[24] In addition, considering hypogly-
cemia is a frequent event in liver failure, the close monitoring 
of  blood glucose levels and careful glucose administration 
are required, and intensive insulin therapy should then be 
used with caution.
Some experimental and clinical studies provide important 
insights into specific treatment of  sepsis-associated liver 
dysfunction. Hepcidin protected against LPS-induced liver 
injury in septic animals,[52] and it significantly decreased he-
patic pro-inflammatory cytokine expression and liver injury, 
leading to reduction of  early lethality. Enhanced autophagy 
and reduced apoptosis might also account for the protective 
effects of  hepcidin. CO
2
 pneumoperitoneum could suppress 
hepatic TNF-α and IL-6 expression in sepsis.[53] Histologi-
cal analysis showed a reduced inflammatory infiltration in 
liver in animals subjected to CO
2
 pneumoperitoneum. 
Adiponectin (APN), which is an adipose tissue-derived 
hormone, is known as an anti-inflammatory cytokine. APN 
deficiency elicits the production of  inflammatory media-
tors, including TNF-α, IL-6 and monocyte chemoattractant 
protein (MCP)-1 and aggravates sepsis-induced hepatic 
injury. Administration of  rosiglitazone, which increased the 
plasma APN concentration, significantly lowered plasma 
levels of  inflammatory mediators, including TNF-α, IL-6, 
and MCP-1 during sepsis.[54]
Hyperoncotic albumin has a beneficial effect on liver injury 
and survival in rats with peritonitis-induced sepsis.[55] The 
increased plasma IL-1β, IL-6, nitrite/nitrate concentrations, 
liver iNOS expression, and liver superoxide levels in septic 
rats were attenuated after treatment with hyperoncotic albu-
min. Calcium, a major second messenger in several cellular 
signaling events, is required by the KCs for the generation 
of  iNOS. Under endotoxemic conditions, calcium channel 
antagonists inhibit LPS-mediated iNOS expression by KCs, 
accompanied by a limitation of  hepatocellular injury.[56]
Montelukast, a leukotriene receptor antagonist, abrogates 
LPS-induced response of  liver injury and suppresses the 
release of  inflammatory as well as oxidative stress reaction 
via its antioxidant properties and enhancement of  enzy-
matic antioxidant activities.[57] Flunixin-meglumin, a well 
known non-steroidal anti-inflammatory drug (NSAID), has 
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antioxidant properties and can be used to attenuate liver 
damage in LPS-induced sepsis.[58] Superoxide dismutase, 
which dismutates superoxide to hydrogen peroxide, has 
also been shown to offer protection against LPS-induced 
liver injury.
Some evidence supports the concept that improving the 
microcirculation may prevent or ameliorate sepsis-induced 
liver dysfunction. Pretreatment with dobutamine improves 
survival rate, liver function and hepatic microcirculation 
in septic rats via β1-adrenoceptor activation, in addition 
to its circulatory mechanism.[59] Dexmedetomidine, a 
novel lipophilic imidazole derivative with a high affinity 
for α2-adrenoceptors, has a protective effect on liver injury 
during experimental sepsis. It attenuates central venous 
congestion, hepatic sinusoids congestion and dilation, and 
portal tract inflammation.[60]
Both liver perfusion and hepatic inflammatory response 
in sepsis might be affected by sympathetic nerve activity. 
Thoracic epidural anesthesia, which is associated with re-
gional sympathetic block, reverses sepsis-induced hepatic 
hyperperfusion and reduces leukocyte adhesion in the liver 
of  septic rats.[61] Similarly, modulation of  the sympathetic 
nervous system by blocking α2A-adrenoceptor significantly 
reduced serum levels of  pro-inflammatory cytokines, che-
mokines, liver enzymes (AST and ALT) and lactate.[62] In 
contrast, some catecholamines, mimicking sympathetic 
nerve activity, can induce an inflammatory response and 
exacerbate the hepatic dysfunction observed during sepsis.
Several studies showed the benefit of  antithrombin III 
supplementation therapy for patients with low antithrombin 
III activity in severe sepsis. But the response of  antithrombin 
III activity after supplementation decreases in proportion 
to the severity of  sepsis and liver dysfunction.[63] Liver X 
receptor (LXR) is a transcription factor of  the nuclear 
receptor family, regulating genes involved in metabolism, 
inflammation, and apoptosis. LXRα plays a protective role 
in the development of  liver injury in experimental sepsis.[64]
Therapeutic hypothermia attenuates liver injury in polymi-
crobial sepsis by enhancing the Akt signaling pathway and 
inhibiting apoptosis.[65]
Finally, extracorporeal supportive devices have been advo-
cated to replace the liver function in liver failure; however, 
the complexity of  liver metabolic, synthetic, detoxifying and 
excretory functions makes the extracorporeal hepatic sup-
port extremely difficult. So far, no survival benefit could be 
demonstrated compared with standard medical therapy.[66]
Conclusion
Hepatic dysfunction may be a result of  repeated infection 
or shock, overactivation of  the systemic response, persistent 
microcirculatory failure, or even undesirable side effects 
of  the treatment provided. Early identification of  sepsis-
associated liver dysfunction and early management of  
severe sepsis as recommended are crucial to improve the 
outcome. The precise cellular basis of  sepsis-associated 
liver dysfunction is not completely understood and its con-
sequences remain largely unknown. A better understanding 
of  the pathophysiology of  hepatic response to sepsis will 
lead to further improvement in survival rates.
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